KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition

• Published in: Oncogene 2017-11, Vol.36 (44), p.6177-6189
• Main Authors: Zhong, Y, Yang, J, Xu, W W, Wang, Y, Zheng, C-C, Li, B, He, Q-Y
• Format: Article
• Language: English
• Subjects: 13/106; 13/31; 38/109; 38/89; 631/67/1857; 631/67/395; 631/80/641/1655; 631/80/86/2371; 64/60; 96/95; Animals; Apoptosis; Aurora kinase; Aurora Kinase A - genetics; Binding proteins; Cancer; Cancer cells; Carcinogenesis; Care and treatment; CDC2 Protein Kinase - genetics; cdc25 Phosphatases - genetics; Cdc25B phosphatase; Cell Biology; Cell cycle; Cell division; Cell growth; Cell proliferation; Cell Proliferation - genetics; Cervix; Comparative analysis; Cyclin-dependent kinase; Cyclin-dependent kinases; Diagnosis; DNA microarrays; Feedback; Female; G2 Phase - genetics; Gene expression; Gene Expression Regulation, Neoplastic; HeLa Cells; Human Genetics; Humans; Immunoprecipitation; Internal Medicine; Kinases; Lung Neoplasms - genetics; Lung Neoplasms - pathology; Male; Mass spectrometry; Mass spectroscopy; Medicine; Medicine & Public Health; Mice; Middle Aged; Molecular modelling; Oncology; Original; original-article; Phosphorylation; Prognosis; Proteins - genetics; Proteomics; S phase; Serine; Tissue Array Analysis; Tumorigenesis; Tumors; Uterine Cervical Neoplasms - genetics; Uterine Cervical Neoplasms - pathology; Xenograft Model Antitumor Assays
• ISSN: 0950-9232; 1476-5594
• DOI: 10.1038/onc.2017.287

Cell cycle dysregulation leads to uncontrolled cell proliferation and tumorigenesis. Understanding the molecular mechanisms underlying cell cycle progression can provide clues leading to the identification of key proteins involved in cancer development. In this study, we performed proteomics analysis to identify novel regulators of the cell cycle. We found that potassium channel tetramerization domain containing 12 (KCTD12) was significantly upregulated in M phase compared with S phase. We also found that KCTD12 overexpression not only facilitated the G2/M transition and induced cancer cell proliferation, but also promoted the growth of subcutaneous tumors and Ki-67 proliferation index in mice. Regarding the mechanism underlying these phenomena, cyclin-dependent kinase 1 (CDK1) was identified as an interacting partner of KCTD12 by immunoprecipitation and mass spectrometry analysis, which showed that KCTD12 activated CDK1 and Aurora kinase A (Aurora A) and that the effects of KCTD12 on CDK1 phosphorylation and cell proliferation were abrogated by cell division cycle 25B (CDC25B) silencing. In addition, Aurora A phosphorylated KCTD12 at serine 243, thereby initiating a positive feedback loop necessary for KCTD12 to exert its cancer-promoting effects. Furthermore, we analyzed the expression levels of various genes and the correlations between the expression of these genes and survival using tumor tissue microarray and Gene Expression Omnibus (GEO) data sets. The data showed that KCTD12 expression was significantly upregulated in cervical and lung cancers. More importantly, high KCTD12 expression was associated with larger tumor sizes, higher pathological stages and poor patient survival. Collectively, our study demonstrate that KCTD12 binds to CDC25B and activates CDK1 and Aurora A to facilitate the G2/M transition and promote tumorigenesis and that Aurora A phosphorylates KCTD12 at serine 243 to trigger a positive feedback loop, thereby potentiating the effects of KCTD12. Thus, the KCTD12-CDC25B-CDK1-Aurora A axis has important implications for cancer diagnoses and prognoses.